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Cruzipain (Cz) is the major cysteine protease of the protozoan Trypanosoma cruzi, etiological agent of Chagas disease. A
conformation-independent classifier capable of identifying Cz inhibitors was derived from a 163-compound dataset and later
applied in a virtual screening campaign on the DrugBank database, which compiles FDA-approved and investigational drugs. 54
approved drugs were selected as candidates, 3 of which were acquired and tested on Cz and T. cruzi epimastigotes proliferation.
Among them, levothyroxine, traditionally used in hormone replacement therapy in patients with hypothyroidism, showed dose-
dependent inhibition of Cz and antiproliferative activity on the parasite.
1. Introduction
Chagas disease is a tropical parasitic disease caused by
the flagellate protozoan Trypanosoma cruzi. T. cruzi life-
cycle includes both vertebrate and invertebrate hosts. 80 to
90% of infections in humans occur when haematophagous
triatomine bug feces come into contact with wounded skin or
mucosae [1]. Other infection ways include blood-transfusion
and congenital transmission. Even though a series of con-
trol campaigns developed by World Health Organization
(WHO), Pan American Health Organization (PAHO), and
national authorities have considerably reduced Chagas dis-
ease incidence in the last fifteen years, there are still almost 8
million infected people and 28 million people at risk [2–4].
Current treatment against Chagas relies on only two
drugs developed during 1960s–1970s, namely, nifurtimox and
benznidazole, which are not effective in the late chronic phase
of the disease and present severe side effects and resistance
issues [5–7]. It is worth noting, however, that important
advances have been made in the fields of biochemistry and
molecular biology of T. cruzi and novel antichagasic thera-
peutics [4, 8–11]. Cysteine protease inhibitors are among the
most investigated candidates against T. cruzi [11]. Cruzipain
(Cz), the major cysteine protease of the parasite, has been
particularly explored as new drug target (a model of the
enzyme is presented in Figure 1). This enzyme has proven to
be essential for replication of the intracellular form of T. cruzi
and plays a role in host-parasite interactions [12]. It is believed
that Cz inhibition produces accumulation of the inactive
precursor of the proteinase within the Golgi complex, which
eventually leads to osmotic shock and cell death [13].
Virtual screening encompasses the application of a diver-
sity of computational methods (models or algorithms) to
chemical libraries or databases, in order to prioritize which
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Figure 1: (a) Model of the cruzipain. (b) Active site of cruzipain.
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Figure 2: An example of MCS. The MCS of the three structures is depicted in red.
of the library compounds will be sent to experimental (in
vitro or in vivo) testing. Here, we present a 2D classifica-
tion model derived from a 163-compound dataset of Cz
inhibitors and noninhibitors. The model was later applied
in a virtual screening (VS) campaign to explore the small
molecule database DrugBank in order to identify novel
Cz reversible inhibitors. DrugBank compiles FDA-approved
and experimental drugs [14, 15], being particularly helpful
to conduct VS campaigns aimed to drug repurposing (i.e.,
searching new therapeutic indications for already known
drugs). Traditionally, second medical uses emerged from
intelligent exploitation of approved or investigational drugs
side effects (e.g., to exploit the aspirin antiplatelet effect to
prevent heart attacks and strokes or the use of sildenafil
to treat erectile dysfunction). Lately, however, knowledge-
based, rational drug repositioning (chemoinformatics- and
bioinformatics-based and others) has gained attention [16–
19] and is being increasingly used to aid in discovering novel
treatments for rare, neglected, and poverty-related conditions
[20–22].
2. Materials and Methods
2.1. Dataset Compilation and Splitting. Building a computa-
tional model capable of discriminating active from inactive
chemical compounds involves three fundamental steps. First,
a dataset of chemical compounds whose class (active or
inactive) has been experimentally determined should be
compiled. Second, the dataset must be partitioned into a
training set that will be used to infer (or train or cali-
brate) the model and an independent (hold-out) test set
that will be used to assess the model predictive ability.
Ideally, the training set should present an adequate bal-
ance of the active and inactive classes so that the inferred
model is not biased. In our case, a 163-compound balanced
dataset including 82 Cz reversible inhibitors and 81 nonin-
hibitors was compiled from literature [23–34]. The dataset
is available as Supplementary Material available online at
http://dx.doi.org/10.1155/2014/279618. A relevant issue that
should be addressed is how to split the dataset into repre-
sentative training and test sets. It has been demonstrated
that random partition is an adequate approach whenever
training and test sets of similar size are selected, but more
rational sampling approaches provide better results when test
sets are small compared to the correspondent training sets
[35, 36]. Following the latter criteria, the LibraryMCS v0.7
(ChemAxon) hierarchical clustering approach was applied
in combination with the k-means clustering implemented in
Statistica 10 Cluster Analysis module (Statsoft Inc, 2011). The
fundamental idea is to identify, within the diverse dataset,
groups of common chemical features to guide the selection
of adequate training and test sets. LibraryMCS relies on
similarity-guidedmaximum common substructure (MCS) to
cluster a set of chemical structures without exhaustive pair-
wise comparison. Covalently bonded atoms are regarded as a
mathematical “graph” where an atom and a bond correspond
to a vertex and an edge, respectively. A common substructure
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is defined as a substructure present in two molecules with
the same atom types and bond connections. The MCS is
defined as the common substructure with the largest number
of atoms or bonds (see Figure 2, e.g.) [37]. LibraryMCSbuilds
the similarity matrix for the input structures and finds the
MCS for the two most similar molecules. This MCS is then
used to create and populate a cluster through substructure
search. Such procedure is repeated iteratively until no pair
of structures with similarity above a similarity threshold is
found, in which case singletons are generated. Similarity-
guidedMCS search is used to findMCS ofmultiple structures
efficiently, without exhaustive pairwise comparison. Thus,
LibraryMCS leads to reproducible but approximate solutions
[38]. Since the number of clusters in k-means clustering
analysis is a user-defined parameter, hierarchical clustering
has been applied here to define an initial partition of “𝑛”
objects into “g” groups, as suggested by Everitt et al. [39],
and the groups of compounds were later optimized by k-
means algorithm, minimizing the Euclidean distance to the
group centers. A smallest common substructure of at least 9
atoms was used, and a randomly selected member from the
clusters defined by the hierarchical approachwas used as seed
in the k-means clustering procedure. A series of descriptors
computed with Dragon 6.0 (Milano Chemometrics, 2012)
representing different aspects of molecular structure (viz.,
molecular weight, log P, polar surface area, number of H
bonds acceptors, information index of atomic content, sum
of atomic van der Waals volumes) were normalized and
applied to calculate Euclidean distance. Once the clusters
were separately identified in the inhibitors and noninhibitors
categories, 25% of each cluster was assigned to an indepen-
dent test set for validation purposes, while the remaining 75%
of the clusters were retained as training set for modeling pur-
poses.The structures of both training and test set compounds
are provided as Supplementary Information.
2.2. Descriptor Calculation andModeling. Molecular descrip-
tors are numerical variables that reflect different aspects
of molecular structure; as such, they are useful to derive
quantitative structure-activity relationships. A total of 3764
0D–2D molecular descriptors were computed with Dragon
6.0 Academic version (Milano Chemometrics. 2010). Since
the values of such descriptors are conformation independent,
they are particularly suitable for their application in VS
campaigns, requiring no preprocessing (e.g., conformational
analysis or optimization) of the screened database structures.
From the 3764 descriptors, 25 random subsets of no more
than 254 descriptors were generated, and these subsets were
used as descriptor pools for modeling purposes (random
subset approach).
Linear Discriminant Analysis (LDA) was then conducted
in order to derive a classification model capable of dis-
tinguishing Cz inhibitors from noninhibitors. LDA is a
qualitative supervised learning method aimed to finding a
linear combination of independent variables to differentiate
between two or more categories of objects. Each object class
is associated with a given value (an integer value) of an
arbitrary variable that serves as class label. In our case, only
two object classes (ACTIVE-Cz inhibitors and INACTIVE-
noninhibitors) were considered; thus the class label assumes
two observed values (1 and −1, resp.). Since the output of the
function being searched is not a continuous variable but only
an object category, LDA and other classificatory techniques
may be useful to handle noisy data, for example, if a given
experimental endpoint is associated with large variability
or if experimental data from a diversity of laboratories are
compiled [40].
The Discriminant Analysis module of Statistica 10 was
used to build the models. A tolerance value of 0.5 was
selected in order to exclude highly correlated descriptors
from the model. All the coefficients linked to the models
descriptors were significant at a 0.05 level. A minimum ratio
of 15 between the number of training set compounds and
the number of independent variables was used in order
to reduce the chances of overfitting. Overfitting refers to
gaining explanatory power on the training set compounds
at the cost of losing predictive ability. Parsimony principle,
Wilks’ lambda, and the performance of the model on the
independent test set were used to select the best model.
Standard validation approaches (stratified leave-group out
cross-validation, randomization test, and external validation)
were used to assess the model’s robustness and predic-
tive ability [41]. Stratified 20-fold cross-validation and 30
randomization tests were applied. Cross-validation implies
removing training set compounds, regenerating the model
and using this new model to predict the removed cases.
Randomization implies scrambling the dependent variable
among the training set compounds (thus abolishing the
structure-property relationship) and obtaining a new, “ran-
domized” model, which should theoretically perform poorly
compared to the actual model.
2.3. Simulated Virtual Screening Campaign. An issue that
emerges from using a reduced dataset (such as our 42-
compound test set) to assess the performance of ranking
methods in virtual screening is that the metrics used to such
purpose exhibit a higher variance compared to significantly
large datasets. Experiments conducted by Truchon and Bayly
[42] show that the standard deviations associatedwith several
frequently used metrics (among them the ROCAUC) are
higher for small datasets and converge to a constant value
when the size of the dataset increases.
Another problem is related to the high ratio of inactives
which mainly hinders the early recognition ability in what
is known as the “saturation effect.” That is, for datasets
with a high ratio of hits (in our case, Cz inhibitors), once
hit compounds saturate the early part of the ordered list,
the enrichment metric cannot get any higher. To estimate
in a more realistic way the utility of our model in a real
virtual screening approach, we have dispersed our test set
among 444 putative noninhibitors acting as decoys. Such
putative noninhibitors are highly similar compounds (0.95
similarity or more) to the test set noninhibitors and have
been retrieved from PubChem. This simulated database
thus contains 21 known Cz-inhibitors among 465 known
or putative noninhibitors; that is, the Cz-inhibitors ratio is
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less than 0.05, representing a more challenging set to assess
the enrichment ability of our models. Note that some of
these putative noninhibitors (decoys) might actually be Cz-
inhibitors; thus, the true performance of our models may be
even higher than the one obtained through this simulated
experiment.
2.4. Virtual Screening. DrugBank 3.0, a chemical database
which compiles FDA approved and investigational drugs, was
screened. Only approved and experimental small molecules
and nutraceuticals (6684 total compounds) were considered
(biotech drugs were excluded a priori). Pharmacological
Distribution Diagrams (PDD) and separate Receiver Operat-
ing Characteristic (ROC) curves were constructed for both
the training and test sets, in order to select the discrimant
function score threshold value determining and adequate
sensitivity/specificity ration, to be used in the VS campaign
[43, 44]. ROC curves provide graphical insight into the
specific-sensitivity balance for different model score thresh-
olds, allowing selection of an appropriate threshold on the
basis of context-dependent criteria. To build ROC curves
MedCalc ROC curves analysis tool was applied (MedCalc
software, 2012).
2.5. Inhibitory Effect on Cz Activity Assay. To study the
effect of the selected compounds on Cz activity, the enzyme
was partially purified by ammonium sulfate precipitation
followed by affinity column chromatography on concanavalin
A-sepharose (Sigma), as previously described [45].The activ-
ity of the partially purified Cz was assayed with 250 𝜇M
Bz-Pro-Phe-Arg-pNA (Sigma) as substrate, incubated in a
buffer of 6, 5 𝜇M dithiothreitol (DTT) and 50mM Tris-HCl
pH 7 [46], in presence or absence of diverse compounds.
The reaction was measured spectrophotometrically at room
temperature at 410 nm for 5min (Beckman CoulterTM
DU530 Life Science UV-vis spectrophotometer). The values
obtained were converted into pmol of hydrolyzed substrate
per min by using the extinction coefficient 8.800M−1 cm−1
(p-nitroanilines). The inhibitory effect of the selected candi-
dates was expressed as a percentage of residual activity of Cz
with respect to the assay without inhibitors.
2.6. Inhibitory Effects on T. cruzi Epimastigote Proliferation.
Epimastigotes of the T. cruzi strain Y were cultured at 28∘C
in BHTmediumwith 20mg/LHaemin, 20% heat-inactivated
fetal calf serum and antibiotics (100 𝜇g/mL streptomycin and
100U/mL penicillin) [47] adding the indicated levothyrox-
ine concentration (0–200𝜇M). Cultures were initiated at
106 cells/mL, and the proliferation was followed daily by cell
counting in a hemocytometer chamber. In order to follow the
effect of the drug on proliferation for long periods, once the
cultures reached the stationary phase (each 7 days), they were
restarted by dilution at 107 cells/mL with fresh medium plus
levothyroxine.
3. Results and Discussion
Clustering procedure revealed 5 groups of at least 6 com-
pounds in the ACTIVE category and 7 groups of at least
7 compounds in the INACTIVE class. According to MCS
clustering, there are 4 compounds in theACTIVE class which
can be considered outliers (singletons or groups of only two
compounds, meaning they share noMCS above the specified
number of atoms with othermolecules from the set), whereas
the INACTIVE category presents 14 outliers. On the basis of
the clustering procedure, 25% of each cluster was assigned
to the test set for external validation purposes, while the
remaining 75% of each cluster was assigned to the training
set upon which the model was derived.
The following model was obtained through LDA:
Class = 0.819 + 0.536 ∗ VE1 X − 1.187 ∗ C-018
+ 0.495 ∗ F-048 − 0.688 ∗NsssN − 0.187 ∗H-051
− 0.427 ∗O-056 − 0.09 ∗ Sds−5.311 ∗ SpPosA A,
(𝑁 = 121, 𝜆 = 0.445, 𝐹 (8, 112) = 17.476, 𝑝 < 0.00001) ,
(1)
where VE1 X represents the sum of the coefficients of the
eigenvector associated with the last (largest negative) eigen-
value of the chi matrix. Such matrix is a modified adjacency
matrix, obtained by weighting each bond between pairs of
vertices by the edge connectivity [48].The elements of the chi
matrix are define as follows:
𝑋
𝑖,𝑗
=
{
{
{
1
√𝑚 × 𝑛
if 𝑖, 𝑗 are adjacent
0 otherwise,
(2)
where 𝑚 and 𝑛 are the valences of the vertices involved.
C-018 is the number of =CHX (= representing a double
bound and X being a heteroatom), F-084 denotes the number
of atoms F attached to carbons SP2, NsssN represents the
number of tertiary nitrogens, H-051 is the number ofH atoms
attached to an alpha carbon, O-056 denotes the number
of groups OH, Sds symbolizes the sum of the E-states of
the =S atom type (thus providing information about the
electron accessibility and the count of the number of atoms
of such atom-type) and SpPosA A is the normalized spectral
positive sum from adjacency matrix. The magnitudes of the
beta coefficients of such descriptors are, respectively, 0.564,
0.185, 0.168, 0.160, 0.137, 0.135, 0.142, and 0.108, showing
that VE1 X is the most relevant independent variable of the
model. It should be highlighted that the model presents a
good cases per predictor ratio (around 15) which indicates a
low chance of overfitting, as confirmed later in the external
validation results. When using 0 as a score threshold to
differentiate active from inactive compounds, the model
presents 87% of good classifications among the training set
inactive compounds, 90% of good classifications among the
training set active compounds, and an overall of 88% good
classifications. Regarding the test set, the model accurately
classifies 81% of the active and 90.5% of the inactive com-
pounds, with an overall good classification of 86%. These
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results seem to confirm that no overfitting has occurred,
since the performance on the test set is very similar to the
performance on the training set. The average performance of
the randomized models was 68.4 (sd = 4.1) showing that
the randomized models were significantly outperformed by
the actual model, as expected. Cross-validation resulted in
an average percentage of good-classifications of 79% (average
of the result of the 20 folds); remarkably, among the worst-
classified folds we found 5 of the outliers detected by the
hierarchical clustering procedure.
We resorted to PDD andROC curves in order to optimize
the chosen threshold score on a rational basis [40, 41].
Figures 3 and 4 present, respectively, the PDDs of the training
and test sets, the ROC curves for the training set, test
set, and the 486-compound simulated database. The area
under the curve (AUC) for the training and test sets ROC
curves was, respectively, 0.930 and 0.923 (1 represents perfect
classification, while 0.5 represents random classification).
0.06 was selected as the cutoff value to differentiate active
from inactive compounds in the VS campaign. According to
the ROC curves data, this value corresponds to a sensitivity
of 87% and a specificity of 88% in the training set, and a
sensitivity of 81% and a specificity of 95% in the test set.
As stated by Triballeau in the original application of ROC
curves to VS [41], the selection of a given balance between
sensitivity and specificity is not a statistical matter but a
context-dependent decision. In our case, due to a limited
budget to acquire and test compounds, we have prioritized
specificity (i.e., reducing the chance of false positives) over
sensitivity.This means that, in order to increase the chance of
having positive results in the biological tests, we risk losing
potentially valuable structural motifs.
Remarkably, our simulated VS campaign resulted in a
ROC AUC of 0.953 (larger, in fact, that the ROC AUCs
obtained for the training and test sets). Furthermore, 16 out
of 21 Cz inhibitors in the dataset (76% of the total number
of inhibitors) appear among the 5% best ranked compounds
from the simulated database.
From 6684 small approved and investigational molecules
of the DrugBank 3.0 database, 64 candidates were selected,
with a score above the selected threshold; 54 of them
correspond to approved drugs, which are the straightfor-
ward candidates for repositioning purposes. On the basis of
their accessibility, 3 of them (Figure 5) were acquired and
experimentally tested in the enzymatic assay on Cz. The
acquired candidates were cisapride (gastroprokinetic agent,
increases motility in the gastrointestinal tract), paroxetine
(antidepressant, a selective inhibitor of serotonin reuptake),
and levothyroxine (used in hormone replacement therapy in
patients with hypothyroidism). Among them, only paroxe-
tine had been previously tested on cruzipain (with negative
results) through a quantitative high-throughput screening
approach which assessed the effect of more than 197,000
candidates on the hydrolysis of the fluorogenic substrate Z-
Phe-Arg-AMC [49].
Using Bz-Pro-Phe-Arg-pNA as chromogenic substrate,
levothyroxine showed a significant inhibitory effect on T.
cruzi Cz activity (Figure 6(a)). Such inhibition proved to be
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Figure 3: PDD showing the distribution of training and test set
active and inactive compounds along the score values of the model.
An acceptable superposition between both sets can be observed.
dose dependent on purified Cz, with an IC50 of 38.43 ±
6.82 𝜇M (Figure 6(b)).
T. cruzi epimastigotes proliferation was affected by
levothyroxine progressively in time and in a dose-dependent
manner (Figure 7). The effect was clearly notorious on the
third week of assay showing a median inhibitory dose (ID
50
)
of 121.76±11.39 𝜇Mat the middle log phase of controls (17th
day).
4. Conclusions
An 8-descriptor conformation-independent classification
model was derived from a 163-compound dataset which
compiled Cz inhibitors and noninhibitors extracted from
the literature. The model presented an excellent case to
descriptor ratio and similar performance on both the training
and the test sets which suggest good predictive ability and
absence of overfitting. Since only conformation-independent
descriptors were included in the model, it is particularly
suitable for efficient exploration of drug libraries through VS
campaigns without requiring any preprocessing of the library
structures.
Having in mind the potential of knowledge-based drug
repositioning to develop novel therapies for neglected and
rare diseases, the model was applied in a VS campaign
to select potential antichagasic drugs from the DrugBank
database, which compiles approved and investigational active
ingredients. PDD and ROC curve analysis were conducted in
order to select a score cutoff value to differentiate active and
inactive agents on a rational basis.
Three candidates were acquired and experimentally
tested in enzymatic and inhibitory assays. Among them,
levothyroxine (traditionally used in hormone replacement
therapy in patients with hypothyroidism) showed a dose-
dependent inhibition on Cz activity with concomitant effects
on T. cruzi proliferation. The results exemplify the potential
of computer-aided drug repositioning in the search of novel
medications for poverty-related diseases.
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Figure 4: Training set (a), test set (b), and simulated database (c) ROC curves.
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Figure 6: (a) Inhibitory effect of the three selected candidates on purified Cz activity. The final concentration of each compound was 50𝜇M.
Protease activity is expressed as percentage of the control condition (2% DMSO). (b) Dose-dependent inhibitory effect of levothyroxine on
purified Cz activity. Levothyroxine was assayed in a concentration range of 0–200 𝜇M. Remanent Cz activity was expressed as a percentage
respect to the control (0𝜇M levothyroxine, 2% DMSO). Asterisks indicate significant differences (∗𝑃 < 0.05).
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Figure 7: Effect of levothyroxine onT. cruzi epimastigotes prolifera-
tion. To determine the growth rate, 107 cells/mLwere seeded in BHT
medium and cultured at 28∘C with the indicated concentrations of
the drug; the control condition was done with 0 𝜇M levothyroxine,
2% DMSO. Parasites were counted daily using a hemocytometer
chamber and, once they reached the stationary phase, were rediluted
at 107 cells/mL with fresh medium plus the indicated levothyroxine
concentration. Results represent the mean ± SD of a representative
experiment.
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